Literature DB >> 28572121

Individualised risk in patients undergoing lung volume reduction surgery: the Glenfield BFG score.

Neil J Greening1,2,3, Paul Vaughan4,3, Inger Oey4, Michael C Steiner5,2,6, Mike D Morgan5, Sridhar Rathinam4, David A Waller4.   

Abstract

Lung volume reduction surgery (LVRS) has been shown to be beneficial in patients with chronic obstructive pulmonary disease, but there is low uptake, partly due to perceived concerns of high operative mortality. We aimed to develop an individualised risk score following LVRS.This was a cohort study of patients undergoing LVRS. Factors independently predicting 90-day mortality and a risk prediction score were identified. Reliability of the score was tested using area under the receiver operating characteristic curve (AUROC).237 LVRS procedures were performed. The multivariate analysis factors associated independently with death were: body mass index (BMI)<18.5 kg·m-2 (OR 2.83, p=0.059), forced expiratory volume in 1 s (FEV1)<0.71 L (OR 5.47, p=0.011) and transfer factor of the lung for carbon monoxide (TLCO) <20% (OR 5.56, p=0.031). A risk score was calculated and total score assigned. AUROC for the risk score was 0.80 and a better predictor than individual components (p<0.01). The score was stratified into three risk groups. Of the total patients, 46% were classified as low risk. Similar improvements in lung function and health status were seen in all groups. The score was introduced and tested in a further 71 patients. AUROC for 90-day mortality in this cohort was 0.84.It is possible to provide an individualised predictive risk score for LVRS, which may aid decision making for both clinicians and patients.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28572121     DOI: 10.1183/13993003.01766-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Postoperative complications and management after lung volume reduction surgery.

Authors:  Max Lacour; Claudio Caviezel; Walter Weder; Didier Schneiter
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 2.  The role of the multidisciplinary emphysema team meeting in the provision of lung volume reduction.

Authors:  Inger Oey; David Waller
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Lung volume reduction surgery in patients with low diffusion capacity.

Authors:  Helen Weaver; Neil J Greening; Sridhar Rathinam
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

4.  Update in Chronic Obstructive Pulmonary Disease 2017.

Authors:  William Z Zhang; Kazunori Gomi; Seyed Babak Mahjour; Fernando J Martinez; Renat Shaykhiev
Journal:  Am J Respir Crit Care Med       Date:  2018-06-15       Impact factor: 21.405

5.  Living with COPD: the struggle for breath and for lung volume reduction therapies.

Authors:  Ravi Mahadeva; Zaid Zoumot
Journal:  ERJ Open Res       Date:  2018-04-20

6.  CELEB trial: Comparative Effectiveness of Lung volume reduction surgery for Emphysema and Bronchoscopic lung volume reduction with valve placement: a protocol for a randomised controlled trial.

Authors:  Sara Buttery; Samuel V Kemp; Pallav L Shah; David Waller; Simon Jordan; John T Lee; Winston Banya; Michael C Steiner; Nicholas S Hopkinson
Journal:  BMJ Open       Date:  2018-10-17       Impact factor: 2.692

7.  Lung volume reduction eligibility in patients with COPD completing pulmonary rehabilitation: results from the UK National Asthma and COPD Audit Programme.

Authors:  Sara C Buttery; Adam Lewis; Samuel V Kemp; Winston Banya; Jennifer K Quint; Michael C Steiner; Nicholas S Hopkinson
Journal:  BMJ Open       Date:  2020-11-27       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.